CN111175521B - Preparation method of fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside - Google Patents
Preparation method of fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside Download PDFInfo
- Publication number
- CN111175521B CN111175521B CN202010014806.1A CN202010014806A CN111175521B CN 111175521 B CN111175521 B CN 111175521B CN 202010014806 A CN202010014806 A CN 202010014806A CN 111175521 B CN111175521 B CN 111175521B
- Authority
- CN
- China
- Prior art keywords
- antibody
- fluorescent
- sample
- lymph node
- node metastasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a preparation method of fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis beside a bed, which comprises a bottom plate, a chromatographic membrane, water absorbing paper, a sample pad and a binding pad; the binding pad is coated with fluorescent microspheres coupled with calcitonin antibody 1 or antibody 5; the chromatographic membrane is provided with a detection line and a quality control line, and the quality control line is coated with an antibody of the anti-antibody 1 or 5 homologous IgG; the detection line is coated with the calcitonin antibody 5 or antibody 1. The invention preferably selects calcitonin as a detection index of thyroid medullary cancer and lymph node metastasis bedside, preferably selects and combines antibodies with good specificity from a plurality of antibodies, and the fluorescent microsphere coupled antibodies are matched with the detection line membrane drawing antibodies, so that the detection sensitivity and the specificity are obviously improved, the deviation is small, and the rapid and accurate detection is realized.
Description
Technical Field
The invention relates to a fluorescent immunochromatography test paper and a preparation method and a product thereof, in particular to a preparation method of a fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis beside a bed; belongs to the technical field of biological medicine.
Background
Medullary thyroid carcinoma (medullary thyroid carcinoma, MTC) is a malignancy that originates from C cells of the thyroid follicular side cells. The C cells are neuroendocrine cells, which synthesize and secrete hormones such as calcitonin, calcitonin gene related peptide and the like, and the C cells are attributed to amine precursor uptake and decarboxylation reaction cells, so that the disease is one of neuroendocrine system tumors. MTC is less common in clinic, and domestic statistics account for about 5% -10% of thyroid cancers. The accurate preoperative diagnosis can help to select proper operation and treatment modes, avoid secondary operation and is extremely important for clinical and patients. At present, fine needle aspiration cytology (fine needle aspiration cytology, FNAC) is the first choice method for the initial diagnosis of medullary thyroid cancer, but the morphology features of the histology and cytology of the medullary thyroid cancer are very complex, and are difficult points in the cytological diagnosis of thyroid. At present, the sensitivity of FNAC for the initial diagnosis of medullary thyroid carcinoma is far from meeting the clinical needs.
Disclosure of Invention
This section is intended to outline some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section as well as in the description summary and in the title of the application, to avoid obscuring the purpose of this section, the description summary and the title of the invention, which should not be used to limit the scope of the invention.
As one of the aspects of the invention, the invention provides a preparation method of fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside.
In order to solve the technical problems, the invention provides the following technical scheme: a method for preparing fluorescent immunochromatography test paper for rapid identification of medullary thyroid carcinoma and lymph node metastasis beside a bed comprises a bottom plate, a chromatographic membrane, water-absorbing paper, a sample pad and a binding pad; the binding pad is coated with fluorescent microspheres coupled with calcitonin antibody 1 or antibody 5;
the chromatographic membrane is provided with a detection line and a quality control line, and the quality control line is coated with an antibody of the anti-antibody 1 or 5 homologous IgG; the detection line is coated with the calcitonin antibody 5 or antibody 1.
As a preferable scheme of the preparation method of the fluorescent immunochromatographic test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside, the invention has the following advantages: the addition amount of the antibody on the binding pad is 200-400 mug antibody/mg fluorescent microsphere.
As a preferable scheme of the preparation method of the fluorescent immunochromatographic test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside, the invention has the following advantages: the content of the fluorescent microsphere on the bonding pad is 1-10 mug/cm 2 。
As a preferable scheme of the preparation method of the fluorescent immunochromatographic test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside, the invention has the following advantages: the antibody content on the quality control line is 0.5-2 mug/cm.
As a preferable scheme of the preparation method of the fluorescent immunochromatographic test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside, the invention has the following advantages: the antibody content on the detection line is 0.5-2 mug/cm.
As a preferable scheme of the preparation method of the fluorescent immunochromatographic test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside, the invention has the following advantages: the amino acid sequence of the calcitonin is CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP.
As a preferable scheme of the preparation method of the fluorescent immunochromatographic test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside, the invention has the following advantages: the fluorescent microsphere has europium as a fluorescent substance.
As a preferable scheme of the preparation method of the fluorescent immunochromatographic test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside, the invention has the following advantages: the chromatographic membrane is a nitrocellulose membrane.
As a preferable scheme of the preparation method of the fluorescent immunochromatographic test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside, the invention has the following advantages: the thyroid medullary carcinoma and lymph node metastasis bedside are rapidly identified, and the sample to be detected is a puncture tissue sample.
The invention has the beneficial effects that: the invention preferably selects calcitonin as a detection index of thyroid medullary cancer and lymph node metastasis bedside, preferably selects and combines antibodies with good specificity from a plurality of antibodies, and the fluorescent microsphere coupled antibodies are matched with the detection line membrane drawing antibodies, so that the detection sensitivity and the specificity are obviously improved, the deviation is small, and the rapid and accurate detection is realized.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the description of the embodiments will be briefly described below, it being obvious that the drawings in the following description are only some embodiments of the present invention, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art. Wherein:
FIG. 1 is a schematic cross-sectional view of a fluorescence immunochromatographic test strip along a length direction;
FIG. 2 is a schematic plan view of a fluorescent immunochromatographic test strip.
Detailed Description
In order that the above-recited objects, features and advantages of the present invention will become more apparent, a more particular description of the invention will be rendered by reference to specific embodiments thereof.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways other than those described herein, and persons skilled in the art will readily appreciate that the present invention is not limited to the specific embodiments disclosed below.
Further, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic can be included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
Example 1:
the CT (calcitonin) is known in the art, the complete CT (calcitonin) is composed of a single polypeptide chain containing 32 amino acids, the amino acid sequence of which is known in the art and can be found in NCBI and other professional databases, and the specific sequence is as follows:
human CT (1-32):
CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP(SEQ ID NO：1)
the CT antibodies (calcitonin) related to the invention comprise monoclonal antibodies, and are specifically shown in Table 1:
TABLE 1
Specificity identification of CT antibodies:
ELISA is used for detection, CT, procalcitonin (PCT), thyroglobulin (Tg) and Thyroid Stimulating Hormone (TSH) are respectively used as detection antigens to coat ELISA plates, the specific reaction of the selected CT antibodies 1-5 and different proteins is respectively detected by ELISA, normal BALB/c mouse serum is used as negative control, and PBS solution is used as blank control.
Results: antibodies 1 to 5 reacted only positively with CT (P/N > 2.1), whereas Procalcitonin (PCT), neuron-specific enolase (NSE), thyroglobulin (Tg), thyroid Stimulating Hormone (TSH) reacted negatively, indicating that antibodies 1 to 5 screened by the present invention were specific, respectively.
The results show that: CT antibodies 1 to 5 reacted positively with CT (P/N > 2.1) and negatively with Procalcitonin (PCT), the neuron-specific enolase NSE thyroglobulin (Tg), and Thyroid Stimulating Hormone (TSH), respectively, indicating that the antibodies 1 to 5 of the present invention were specific, respectively.
The preparation method of the fluorescent immunochromatography test paper for detecting human CT in the object to be detected comprises the following steps:
1. study object: specimens were obtained from patients with surgery (including MTC patients) in the hospital 100 exception, and thyroid glands (including lesions of suspected MTC patients) and lymph nodes were each intra-operatively punctured by a syringe.
2. Reagents and instrumentation:
the fluorescent microsphere labeled antibody of the immunochromatographic test paper is selected from 1 calcitonin antibody in Table 1, the membrane-dividing antibody on the detection line is selected from another calcitonin antibody in Table 1, the antibody combination which has no cross reaction and is suitable for fluorescent immunochromatographic detection and has high specificity and sensitivity is screened out, the quality control antibody on the quality control line in the immunochromatographic test paper is an antibody of which one antibody is homologous IgG in antibodies 1-5, the carboxylated polystyrene time-resolved fluorescent microsphere and the fluorescence detector are obtained from the original technical and trade company of the Wuxi city, a nitrocellulose membrane (Merck-Millipore company in America), a sample pad, a binding pad, a bottom plate and absorbent paper are purchased from Shanghai Jie one company, and other reagents are home-made analytical purity.
3. The preparation method of the fluorescent immunochromatography test strip comprises the following steps:
3.1 sample pad treatment
The samples were soaked for 5 hours with phosphate buffer, pH7.4, 0.05M containing 1% BSA,0.1% Triton100 and dried.
3.2 preparation of fluorescent microsphere conjugate pad:
washing the fluorescent microspheres with MES activation buffer at ph 4.0; redissolving the mixture to the original volume by using MES buffer solution, adding 1mg/ml carbodiimide (EDC) and 1mg/ml N-hydroxysuccinimide (NHS) in the same volume, and reacting for 20 minutes at room temperature; washing the fluorescent microspheres, re-dissolving the fluorescent microspheres with 0.05M phosphate buffer of pH7.4, adding one of the antibodies 1-5 according to 20 mug of the antibody/mg of the time-resolved fluorescent microspheres, reacting for 2 hours at room temperature, adding 0.05M phosphate buffer of pH7.4 containing 10% BSA to 1% BSA, and reacting for 30 minutes at room temperature; washing the fluorescent microspheres, re-dissolving the fluorescent microspheres with phosphate buffer containing 1% BSA,0.1% Tween-20,0.4% S9,5% sucrose, 0.1% proclin-300,0.05M pH7.4 to 2 times the original volume, and binding one of the antibodies 1 to 5 according to (0.6X30) cm 2 Spraying 56 mug fluorescent microspheres on the bonding pad uniformly, drying for 2 hours at 37 ℃ in dark, preparing into a fluorescent microsphere bonding pad, adding a drying agent, and sealing for later use;
3.3T line and C line scribing antibody
Sticking a nitrocellulose membrane 2 on a PVC bottom plate 1, respectively diluting one of CT antibodies 1-5 and an antibody of anti-antibody 1-5 homologous IgG to 1mg/ml by using a phosphate buffer solution containing 5% of sucrose and having a pH of 0.05M and 7.4, spraying the two on the nitrocellulose membrane at intervals of 0.5cm, drying at 37 ℃ for 6 hours, and then adding a drying agent for sealing and preserving for later use;
3.4 assembling of fluorescent immunochromatographic test strip
And (3) forming a microfiltration system by combining a marked antibody combining pad 5 marked with fluorescent microspheres, a sample pad 4 and absorbent paper 3 on a nitrocellulose membrane base plate (1 and 2) marked with C line and T line antibodies in the environment with humidity less than 35% and temperature of 20-25 ℃, cutting into 0.4cm wide, and filling into a card shell to obtain the test strip (figures 1 and 2). FIG. 1 is a schematic cross-sectional view of a fluorescence immunochromatographic test strip along a length direction; FIG. 2 is a schematic plan view of a fluorescent immunochromatographic test strip; the reference numerals in the drawings are as follows: 1-bottom plate, 2-nitrocellulose membrane, 3-absorbent paper, 4-sample pad, 5-binding pad, 6-quality control zone, 7-detection zone.
4. The detection method comprises the following steps:
4.1 sampling: the isolated suspected medullary thyroid cancer tissue was punctured with a fine needle of a 26-gague syringe needle 5 times in total at each location of the same tissue, and after sampling, a 1ml syringe was connected to the rear of the needle.
4.2 sample pretreatment: a solution tube containing 200. Mu.l PBS buffer was taken, equilibrated to room temperature, and all the liquid was ensured to be at the bottom of the tube before use. The syringe after the puncture of the fine needle is stretched into buffer solution, sucked and beaten to be fully washed and uniformly mixed, and 200 mu l of sample to be detected is prepared.
4.3, sample adding: 60 mu l of the sample to be detected is added into a sample adding area of the CT fluorescence immunochromatography test paper, and the sample is subjected to thin film chromatography reaction in an incubator for 5 minutes.
4.4, detection: and inserting the reacted fluorescent immunochromatographic test paper and a calibration card into a bayonet of a portable fluorescent immunochromatographic quantitative analyzer, operating the instrument, and automatically reading the card by the instrument to give a quality control zone C value and a detection zone T value in the fluorescent immunochromatographic test paper. It took 7 minutes to complete the entire test procedure.
4.5, judging the result:
when T/C is more than or equal to 0.5, the result is positive, which indicates that CT concentration in tissue fluid of the puncture object is higher, and the puncture object can be identified as MTC or lymph node metastasis;
when T/C is less than 0.5, the result is negative, which indicates that CT concentration in tissue fluid of the puncture object is lower, and the puncture object can be identified as non-MTC or non-lymph node metastasis.
5. Drawing a standard curve: the CT standard was prepared at 6 different concentrations of 0pg/ml, 10pg/ml, 50pg/ml, 100pg/ml, 500pg/ml, 1000pg/ml, 5 replicates for each concentration.
6. Performance test of fluorescent immunochromatography test strip: (1) sensitivity: 10 blanks were measured, the mean (x) and standard deviation(s) were taken, x.+ -. 2s calculated, and the corresponding dose was found on the standard curve using this value. (2) And (3) respectively extracting the fluorescent immunochromatographic test strips of CT of the same batch and different batches after the test strips are stored for 6 months at the temperature of 4 ℃ under the dark condition, testing by using a standard substance with the concentration of 200pg/ml, and calculating the differences CV between the batch and the batch. (3) The standard was prepared to 6 concentrations corresponding to the CT standard curve for specificity detection.
7. Detection of CT content in different tissue eluents: and respectively taking MTC focus puncture liquid and normal thyroid puncture liquid, and detecting CT content.
8. And (3) statistical treatment: analysis of data with SPSS 19.0 statistical software, and X between groups 2 The difference is statistically significant when P < 0.05 is detected. Correlation and variance comparisons were made using paired t-test.
In example 1, the antibodies 1 to 5 were used as a labeled antibody and a labeled antibody, respectively, and the detection sensitivity, intra-group difference, and inter-group difference of each antibody combination were examined.
Note that: a cut off value of less than or equal to negative and a cut off value of more than or equal to positive
The invention preferably selects calcitonin as a detection index of thyroid medullary cancer and lymph node metastasis bedside, preferably selects and combines antibodies with good specificity from a plurality of antibodies, and the fluorescent microsphere coupled antibodies are matched with the detection line membrane drawing antibodies, so that the detection sensitivity and the specificity are obviously improved, the deviation is small, and the rapid and accurate detection is realized.
Control example:
based on the results of example 1 above, the microsphere-conjugate pad spray buffer was changed to a phosphate buffer of 1% BSA,0.5% Tween-20,5% sucrose, 0.1% proclin-300,0.05M pH 7.2-7.6. The remaining reagents and methods were the same as in example 1, and the test paper was analyzed for performance in the same manner as in example 1.
It should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted without departing from the spirit and scope of the technical solution of the present invention, which is intended to be covered in the scope of the claims of the present invention.
Claims (2)
1. A preparation method of fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside is characterized by comprising the following steps: comprises a bottom plate, a chromatographic membrane, water absorbing paper, a sample pad and a bonding pad; the binding pad is coated with fluorescent microspheres coupled with calcitonin antibody 1;
the chromatographic membrane is provided with a detection line and a quality control line, and the quality control line is coated with an antibody of the anti-antibody 1 homologous IgG; the detection line is coated with a calcitonin antibody 5;
the fluorescent microsphere has europium as a fluorescent substance;
the addition amount of the antibody on the binding pad is 200-400 mug antibody/mg fluorescent microsphere;
the antibody 1 is a monoclonal antibody MAB83503; antibody 5 was monoclonal antibody BS-2174R-2;
the thyroid medullary carcinoma and lymph node metastasis bedside are rapidly identified, and a sample to be detected is a puncture tissue sample;
the antibody content on the quality control line is 0.5-2 mug/cm;
the content of the antibody on the detection line is 0.5-2 mug/cm;
the content of the fluorescent microsphere on the bonding pad is 1-10 mug/cm 2 ；
The chromatographic membrane is a nitrocellulose membrane;
wherein, the spraying buffer solution of the bonding pad is: phosphate buffer containing 1% BSA,0.1% Tween-20,0.4% S9,5% sucrose, 0.1% proclin-300,0.05M pH 7.4;
the preparation method of the sample to be tested comprises the following steps:
(1) Sampling: the isolated suspected medullary thyroid cancer tissue is punctured with a 26-gague syringe needle fine needle for 5 times at each position of the same tissue, and after sampling, the back of the syringe needle is connected with a 1ml syringe;
(2) Sample pretreatment: taking a solution tube containing 200 mu l of PBS buffer solution, balancing to room temperature, extending the syringe needle sampled in the step (1) into the buffer solution, and fully washing and uniformly mixing by a suction syringe to prepare 200 mu l of sample to be tested;
the sample adding method of the sample to be tested comprises the following steps: and (3) adding 60 mu l of the sample to be detected obtained in the step (2) into a sample pad of the fluorescent immunochromatographic test paper, and carrying out thin-film chromatography reaction for 5 minutes in an incubator.
2. The method for preparing the fluorescent immunochromatographic test strip for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside according to claim 1, which is characterized in that: the amino acid sequence of the calcitonin is CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010014806.1A CN111175521B (en) | 2020-01-07 | 2020-01-07 | Preparation method of fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010014806.1A CN111175521B (en) | 2020-01-07 | 2020-01-07 | Preparation method of fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111175521A CN111175521A (en) | 2020-05-19 |
| CN111175521B true CN111175521B (en) | 2024-01-30 |
Family
ID=70649306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010014806.1A Active CN111175521B (en) | 2020-01-07 | 2020-01-07 | Preparation method of fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111175521B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4278188A4 (en) * | 2021-01-17 | 2024-10-30 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | DEVICES AND METHODS FOR DIAGNOSIS OF THYROID DISEASES |
Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2009111105A (en) * | 2009-03-27 | 2009-11-10 | Федеральное государственное учреждение Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального аге | METHOD FOR CHOOSING THE TACTICS OF POST-OPERATIVE TREATMENT OF MEDICAL THYROID CANCER |
| JP2013255485A (en) * | 2012-05-17 | 2013-12-26 | Shizuoka Prefecture | Method for determining medullary thyroid cancer |
| CN104090248A (en) * | 2013-12-24 | 2014-10-08 | 上海容晖生物科技有限公司 | Reagent for quantitative detection of Beta-receptor stimulant through Europium chelate latex time-resolved immunochromatographic assay |
| CN105628919A (en) * | 2014-10-30 | 2016-06-01 | 上海市第十人民医院 | Application of CD166 as liver cancer diagnosis serum marker and kit thereof |
| CN106546725A (en) * | 2016-10-26 | 2017-03-29 | 沈阳优宁生物科技有限公司 | A kind of preparation method and application of rare earth element fluorescent microsphere coupled antibody lyophilized powder |
| CN106771128A (en) * | 2016-12-15 | 2017-05-31 | 威海纽普生物技术有限公司 | Parathyroid hormone determines kit and preparation method |
| CN107167595A (en) * | 2017-07-13 | 2017-09-15 | 深圳市亚辉龙生物科技股份有限公司 | A kind of immunochromatography reagent bar of fluorogenic quantitative detection INHB and preparation method thereof |
| CN107255726A (en) * | 2017-08-02 | 2017-10-17 | 江苏省原子医学研究所 | Quantitatively detect fluorescence immune chromatography test paper of human parathyroid hormone and preparation method thereof |
| CN107340394A (en) * | 2017-06-27 | 2017-11-10 | 赵晖 | The diagnostic system and its operating method of a kind of metastatic carcinoma of bone |
| CN207717778U (en) * | 2016-12-30 | 2018-08-10 | 苏州和锐生物科技有限公司 | TNF-α time-resolved fluoroimmunoassay chromatographs immue quantitative detection reagent box |
| CN108845128A (en) * | 2018-05-04 | 2018-11-20 | 广州敏捷生物技术有限公司 | Immunofluorescence for detecting canine distemper virus antigen chromatographs detection card and preparation method |
| CN109187975A (en) * | 2018-08-08 | 2019-01-11 | 施康培医疗科技（武汉）有限公司 | A kind of medullary carcinoma of thyroid gland joint-detection colloidal gold immuno-chromatography test paper strip |
| CN109270269A (en) * | 2018-09-05 | 2019-01-25 | 河南省生物工程技术研究中心 | A kind of fluorescence immune chromatography detection card, kit for the multi-joint detection of early-stage breast cancer |
| CN109342740A (en) * | 2018-11-28 | 2019-02-15 | 必欧瀚生物技术（合肥）有限公司 | A kind of fluorescence immune chromatography kit and preparation method thereof detecting people's pylori spiral bacilli antibody |
| CN109725148A (en) * | 2018-12-30 | 2019-05-07 | 广东环凯微生物科技有限公司 | A kind of immunomagnetic beads preservation liquid |
| CN109884310A (en) * | 2017-12-25 | 2019-06-14 | 苏州和锐生物科技有限公司 | Enterobacteriaceae ospa polypeptide, antibody capture device and kit |
| WO2019165351A1 (en) * | 2018-02-23 | 2019-08-29 | Board Of Regents, The University Of Texas System | Tissue analysis by mass spectrometry |
| CN110187129A (en) * | 2019-06-26 | 2019-08-30 | 浙江伊利康生物技术有限公司 | C reactive protein detection kit |
| CN110275014A (en) * | 2019-07-23 | 2019-09-24 | 江苏省原子医学研究所 | Quickly identify the method for thyroid papillary carcinoma Cervical Lymph Node Metastasis in a kind of art |
| CN110609025A (en) * | 2019-10-09 | 2019-12-24 | 上海奥普生物医药有限公司 | Time-resolved fluorescence immunochromatographic kit for combined quantitative detection of CRP and SAA and preparation method thereof |
| CN110632297A (en) * | 2018-10-11 | 2019-12-31 | 东莞东阳光医疗智能器件研发有限公司 | Immunoassay kit and determination method and preparation method thereof |
-
2020
- 2020-01-07 CN CN202010014806.1A patent/CN111175521B/en active Active
Patent Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2009111105A (en) * | 2009-03-27 | 2009-11-10 | Федеральное государственное учреждение Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального аге | METHOD FOR CHOOSING THE TACTICS OF POST-OPERATIVE TREATMENT OF MEDICAL THYROID CANCER |
| JP2013255485A (en) * | 2012-05-17 | 2013-12-26 | Shizuoka Prefecture | Method for determining medullary thyroid cancer |
| CN104090248A (en) * | 2013-12-24 | 2014-10-08 | 上海容晖生物科技有限公司 | Reagent for quantitative detection of Beta-receptor stimulant through Europium chelate latex time-resolved immunochromatographic assay |
| CN105628919A (en) * | 2014-10-30 | 2016-06-01 | 上海市第十人民医院 | Application of CD166 as liver cancer diagnosis serum marker and kit thereof |
| CN106546725A (en) * | 2016-10-26 | 2017-03-29 | 沈阳优宁生物科技有限公司 | A kind of preparation method and application of rare earth element fluorescent microsphere coupled antibody lyophilized powder |
| CN106771128A (en) * | 2016-12-15 | 2017-05-31 | 威海纽普生物技术有限公司 | Parathyroid hormone determines kit and preparation method |
| CN207717778U (en) * | 2016-12-30 | 2018-08-10 | 苏州和锐生物科技有限公司 | TNF-α time-resolved fluoroimmunoassay chromatographs immue quantitative detection reagent box |
| CN107340394A (en) * | 2017-06-27 | 2017-11-10 | 赵晖 | The diagnostic system and its operating method of a kind of metastatic carcinoma of bone |
| CN107167595A (en) * | 2017-07-13 | 2017-09-15 | 深圳市亚辉龙生物科技股份有限公司 | A kind of immunochromatography reagent bar of fluorogenic quantitative detection INHB and preparation method thereof |
| CN107255726A (en) * | 2017-08-02 | 2017-10-17 | 江苏省原子医学研究所 | Quantitatively detect fluorescence immune chromatography test paper of human parathyroid hormone and preparation method thereof |
| CN109884310A (en) * | 2017-12-25 | 2019-06-14 | 苏州和锐生物科技有限公司 | Enterobacteriaceae ospa polypeptide, antibody capture device and kit |
| WO2019165351A1 (en) * | 2018-02-23 | 2019-08-29 | Board Of Regents, The University Of Texas System | Tissue analysis by mass spectrometry |
| CN108845128A (en) * | 2018-05-04 | 2018-11-20 | 广州敏捷生物技术有限公司 | Immunofluorescence for detecting canine distemper virus antigen chromatographs detection card and preparation method |
| CN109187975A (en) * | 2018-08-08 | 2019-01-11 | 施康培医疗科技（武汉）有限公司 | A kind of medullary carcinoma of thyroid gland joint-detection colloidal gold immuno-chromatography test paper strip |
| CN109270269A (en) * | 2018-09-05 | 2019-01-25 | 河南省生物工程技术研究中心 | A kind of fluorescence immune chromatography detection card, kit for the multi-joint detection of early-stage breast cancer |
| CN110632297A (en) * | 2018-10-11 | 2019-12-31 | 东莞东阳光医疗智能器件研发有限公司 | Immunoassay kit and determination method and preparation method thereof |
| CN109342740A (en) * | 2018-11-28 | 2019-02-15 | 必欧瀚生物技术（合肥）有限公司 | A kind of fluorescence immune chromatography kit and preparation method thereof detecting people's pylori spiral bacilli antibody |
| CN109725148A (en) * | 2018-12-30 | 2019-05-07 | 广东环凯微生物科技有限公司 | A kind of immunomagnetic beads preservation liquid |
| CN110187129A (en) * | 2019-06-26 | 2019-08-30 | 浙江伊利康生物技术有限公司 | C reactive protein detection kit |
| CN110275014A (en) * | 2019-07-23 | 2019-09-24 | 江苏省原子医学研究所 | Quickly identify the method for thyroid papillary carcinoma Cervical Lymph Node Metastasis in a kind of art |
| CN110609025A (en) * | 2019-10-09 | 2019-12-24 | 上海奥普生物医药有限公司 | Time-resolved fluorescence immunochromatographic kit for combined quantitative detection of CRP and SAA and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone;F Massaro 等;J Endocrinol Invest;32(4);全文 * |
| Routine serum calcitonin measurement in thyroid nodules;María E Storani 等;Medicina (B Aires);79(4);全文 * |
| 穿刺细胞学特征结合血清CT、CEA对诊断甲状腺髓样癌的意义;张海芳;方庆全;姜爱华;张海萍;;诊断病理学杂志(12);全文 * |
| 血清CT、CEA检测在甲状腺髓样癌临床评估中的价值;叶柳青;徐笑红;丁金旺;周国明;沈俊娅;周荣;;中国卫生检验杂志(02);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111175521A (en) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107255726B (en) | Quantitatively detect the fluorescence immune chromatography test paper and preparation method thereof of human parathyroid hormone | |
| JP2002537561A (en) | Methods and apparatus for isolating and analyzing cellular protein components | |
| CN109142758A (en) | It is a kind of to detect the immuno-chromatographic test paper strip of glycosylated hemoglobin, kit and preparation method thereof | |
| CN109188000A (en) | A kind of test strips and preparation method thereof of portable inspectiont human parathyroid hormone | |
| CN107402300B (en) | A kind of method of quick identification human parathyroid | |
| CN111175521B (en) | Preparation method of fluorescent immunochromatography test paper for rapid identification of thyroid medullary carcinoma and lymph node metastasis bedside | |
| CN114609391A (en) | Human placenta growth factor determination kit and preparation method thereof | |
| KR101083420B1 (en) | Autoantibody against Vinculin for breast cancer diagnosis and diagnosis kit using the same | |
| CN111999509A (en) | Anti-mullerian hormone determination kit, preparation method and detection method | |
| CN110275014B (en) | Method for rapidly identifying metastasis of papillary thyroid carcinoma cervical lymph nodes in operation | |
| CN111208308A (en) | Preparation method of fluorescence immunochromatographic test paper for assisting ovarian cancer diagnosis based on FSH rapid detection | |
| JPH0580053A (en) | Immunochemical detection method for human corpus uteri cancer cell | |
| US5955287A (en) | Method of determining level of biological substances elevated in the presence of cancer and other neoplasms | |
| CN109884316B (en) | Kit for detecting tumor M2 type pyruvate kinase and preparation method thereof | |
| Xie et al. | Rapid intraoperative method for the identification of metastatic lymph nodes from thyroid carcinoma | |
| CN111638324A (en) | Coronary heart disease diagnosis biomarker combination and application thereof | |
| CN111044734A (en) | Detection kit for detecting vascular endothelial growth factor, and preparation method and use method thereof | |
| CN113495147A (en) | Application of urine alpha 2-macroglobulin and polypeptide fragment thereof in gestational diabetes | |
| CN111948400A (en) | Test strips for rapid quantitative detection of tissue cell proteins | |
| CN113325183B (en) | Kit for differential diagnosis of EM/FEM | |
| US5668016A (en) | Method of preparing and activating samples for radioimmunoassay and other test | |
| CN116718775B (en) | Composition, test paper and method for detecting colorectal cancer | |
| CN116087519B (en) | A marker for early screening of cardiac adenocarcinoma in high-risk population and its application | |
| CN113447654B (en) | Application of mass spectrometry technology in detecting PSM-E molecular level in urine in preparation of products for early diagnosis of prostate cancer | |
| CN112162049B (en) | Method for detecting sarcosine in urine for non-diagnosis purpose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No.301, Yanchang Middle Road, Jing'an District, Shanghai 200072 Applicant after: Shanghai Tenth People's Hospital Applicant after: Wuxi Jiangyuan industrial technology and Trade Co.,Ltd. Address before: No.301, Yanchang Middle Road, Jing'an District, Shanghai 200072 Applicant before: Shanghai Tenth People's Hospital Applicant before: Wuxi Jiangyuan Industrial Technology and Trade Corp. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |